DrugCendR's Unattributed - II Round

DrugCendR raised a round of funding on May 29, 2018.

DrugCendR is a biopharmaceutical company dedicated to developing next generation cancer therapies that are designed to overcome the barriers of drug delivery to solid tumors. The company's drug delive…

Articles about DrugCendR's Unattributed - II Round: